Today: 3 July 2026

Khadija Saeed

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Microsoft stock rebounds after wipeout, but AI stocks stay jumpy as spending fears bite

Microsoft stock rebounds after wipeout, but AI stocks stay jumpy as spending fears bite

New York, Jan 30, 2026, 10:19 EST — Regular session Microsoft shares held steady on Friday morning, though the broader AI sector showed signs of strain. Investors are grappling with rising data-center costs amid cloud growth that’s failing to accelerate as expected. By 10:03 a.m. ET, Microsoft was up 0.6% at $436.11. Nvidia dipped 0.4%, AMD dropped 4.1%, and the Nasdaq-100 ETF QQQ slipped 0.6%.
30 January 2026
··········
Johnson & Johnson stock price: JNJ closes lower after talc fraud suit tossed — what investors watch next

Johnson & Johnson stock price: JNJ closes lower after talc fraud suit tossed — what investors watch next

New York, January 29, 2026, 21:37 EST — Market closed. Johnson & Johnson shares edged down 0.19% to close at $227.29 on Thursday. The drop came after a U.S. judge dismissed a fraud lawsuit targeting the company’s "Texas two-step" strategy, which involves moving talc liabilities into a subsidiary that then files for bankruptcy. U.S. District Judge Michael Shipp ruled the plaintiffs failed to prove they were harmed by the bankruptcy stays that paused cases from October 2021 through March 2025. J&J’s litigation head, Erik Haas, called the claims “wholly meritless.” During the session, the stock hit $230 and last changed hands at $227.98 in after-hours trading.
30 January 2026
··
1 … 344 345 346 347 348 … 877

Stock Market Today

  • AbbVie Jumps 4%, Tops Apogee Buy Price After Earnings Beat
    July 2, 2026, 7:16 PM EDT. AbbVie Inc. finished up 3.99% at $261.07, a new 52-week high. The stock gained nearly $17.8 billion in market cap, putting it well above the $10.9 billion Apogee Therapeutics deal announced June 22. AbbVie closed above targets from RBC Capital, Investing.com and Google Finance. With Q2 earnings set for July 31, the rally puts the spotlight on analyst target hikes. J.P. Morgan and RBC Capital have backed the Apogee buy for its long-term growth, with the company saying the acquisition will add to EPS by 2032. AbbVie outpaced broader markets, which slipped slightly, as investors bet on the drugmaker's deal strategy.
Go toTop